NeoGenomics Appoints Dr. Barbara Chaitin As Director Of Surgical Pathology And Medical Director For Its Florida Lab
FT. MYERS, Fla., Jan. 4, 2012 /PRNewswire/ -- NeoGenomics, Inc. (NASD OTC BB: NGNM), a leading provider of cancer-focused genetic testing services, announced today the appointment of Dr. Barbara Chaitin as Director of Surgical Pathology for NeoGenomics Laboratories and Medical Director of the Fort Myers, Florida laboratory.
Dr. Chaitin was recently the Director of Esoteric Services, and Chair of the Solid Tumor Committee, at AmeriPath, a division of Quest Diagnostics Inc. Prior to that time, she was National Medical Director and Head of Solid Tumor Services at Genzyme Genetics in New York City. Dr. Chaitin's professional experience also includes service as Associate Medical Director at IMPATH Laboratories in New York City and Bender Laboratory in Albany, New York. Early in her career, she served as a Forensic Pathologist for New York State, and as an Attending Pathologist and Assistant Professor of Pathology at New York University Medical School and Albert Einstein College of Medicine.
Dr. Chaitin attended Albert Einstein College of Medicine, completed her Anatomic and Clinical Pathology Residency at University of California in San Francisco, and completed Fellowships in Surgical Pathology at Stanford University Medical Center and at MD Anderson Cancer Center. She is Board certified in both Forensic Pathology and Anatomic Pathology.Doug VanOort, NeoGenomics Chairman and CEO commented, "Dr. Chaitin brings a wealth of experience and valuable expertise to NeoGenomics. We have strong expertise in the application of molecular genetics in oncology and hematology, and our clients are requesting that we continue to enhance our capabilities for solid tumor pathways and disease. We are looking forward to Dr. Chaitin's medical leadership as we expand our immunohistochemistry offering and introduce new FISH and molecular tests targeted at solid tumor pathology. We are excited to welcome Dr. Chaitin to our Medical Team and to our company."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts